Wednesday, July 8, 2026

Patent intelligence · US

US 9850323

High concentration chitosan-nucleic acid polyplex compositions

granted A61KA61K31/7088
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 11
Applicant portfolio 53
Related coverage 1
Patent details — US 9850323

Quick answer

US 9850323 (High concentration chitosan-nucleic acid polyplex compositions) is held by ENGENE, INC.. Status: granted. Granted Dec 26, 2017. Expires Dec 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
ENGENE, INC.
Grant date
Expiration
Claims
20
CPC classes
A61K, A61K31/7088

More from ENGENE, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12421273

    Ectonucleotidase inhibitors and methods of use thereof

    ANTENGENE THERAPEUTICS LIMITED · Expires Sep 18, 2045

    granted
  2. US 12414968

    Compositions comprising bacterially derived minicells and methods of using the same

    EnGeneIC Molecular Delivery Pty Ltd · Expires Sep 11, 2045

    granted
  3. US 12357687

    Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same

    EnGeneIC Molecular Delivery Pty Ltd · Expires Jul 10, 2045

    granted
  4. US 12337033

    Encapsulated glycolipid antigens for treatment of neoplastic diseases

    EnGeneIC Molecular Delivery Pty Ltd · Expires Jun 19, 2045

    granted
  5. US 12076418

    Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo

    ENGENE, INC. · Expires Aug 29, 2044

    granted
  6. US 11964021

    Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors

    EnGeneIC Molecular Delivery Pty Ltd · Expires Apr 18, 2044

    granted
  7. US 11883433

    Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof

    CELLENGENE INC. · Expires Jan 25, 2044

    granted
  8. US 11858957

    Ectonucleotidase inhibitors and methods of use thereof

    ANTENGENE THERAPEUTICS LIMITED · Expires Dec 28, 2043

    granted

Related coverage

Frequently asked questions

What is US patent 9850323?

US 9850323 (High concentration chitosan-nucleic acid polyplex compositions) is held by ENGENE, INC.. Status: granted. Granted Dec 26, 2017. Expires Dec 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9850323?

ENGENE, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 53 pharmaceutical patents for this assignee.

When does US 9850323 expire?

Our index shows an expiration date of Dec 21, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.